DESCRIPTION (provided by applicant): Her2 is a receptor tyrosine kinase and cellular proto-oncogene that plays a major role in breast and other human cancers. Her2 is a member of the ErbB - epidermal growth factor receptor (EGFR) family. Under physiologic conditions, Her2 functions by heterodimerizing with EGFR, Her3 or Her4 and then activating its tyrosine kinase. We developed a reconstituted in vitro system to study the heterodimerization and enzyme activation of Her2. We will study the structure of Her2 heterodimers using two mass spectrometry (MS) approaches, termed chemical footprinting MS, and we will combine this with molecular dynamics simulations to obtain atom level interpretations of the MS results. Conclusions from MS and molecular dynamics will be functionally tested using Fluorescence Resonance Energy Transfer (FRET) experiments and mutagenesis experiments in cell lines. This proposal will produce a sustained, powerful influence by producing a number of scientific "firsts", chief among them is the first structural study of a Her2-Her3 heterodimer. Her2-Her3 heterodimers form a very potent signaling pair and it is has been shown that knocking down Her3 in Her2- positive breast cancer cell lines reverses oncogenic transformation. Achieving the aims of this project will advance scientific knowledge by providing new structural and functional information on Her2-Her3 and EGFR-Her2 heterodimers. Achieving the aims of this project will also advance clinical practice by identifying which Her2 and Her3 cancer associated mutations likely drive cancer cell growth and are sensitive to Her2 targeted drugs. This information will identify new patients who are likely to benefit from Her2 targeted drugs and will provide the key scientific findings to support a future breast cancer clinical trial.
Public Health Relevance Statement
Her2 is an oncogene that plays a major role in breast, lung, stomach and other human cancers. Obtaining a detailed understanding of the activation process of Her2 will provide new scientific information on an important cancer protein and help guide the use of anti-cancer drugs that target this protein.
NIH Spending Category
BiotechnologyBreast CancerCancerGenetics
Project Terms
Antineoplastic AgentsBindingBiological AssayBiological TestingBreastBreast Cancer CellC-terminalCancer Cell GrowthCancer cell lineCell LineCell ProliferationChemicalsClinicalClinical TrialsColorectal CancerDevelopmentDimerizationDrug TargetingDrug resistanceERBB2 geneEnzyme ActivationEpidermal Growth Factor ReceptorErbB4 geneExtracellular DomainFamilyFamily memberFluorescence Resonance Energy TransferFutureGenesGrowthHeterodimerizationHumanIn VitroIncidenceKnowledgeLengthLungMalignant NeoplasmsMalignant neoplasm of lungMapsMass Spectrum AnalysisMeasuresMediatingMethodsModelingMolecular ModelsMonoclonal AntibodiesMutagenesisMutationNucleotidesOncogenesOncogenicPatientsPertuzumabPhosphotransferasesPhysiologicalPlayProcessProtein Tyrosine KinaseProteinsProto-OncogenesReceptor Protein-Tyrosine KinasesRoleScientific Advances and AccomplishmentsSignal TransductionStomachStructureSystemTailTechniquesTestingTrastuzumabTyrosine Kinase Inhibitorbasecancer cellcell transformationclinical practicedesigndimerimprovedin vivoknock-downlapatinibmalignant breast neoplasmmalignant stomach neoplasmmembermimeticsmolecular dynamicsmolecular modelingmonomeroutcome forecastpublic health relevancereconstitutionresearch study
No Sub Projects information available for 5R01CA161001-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA161001-02
Patents
No Patents information available for 5R01CA161001-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA161001-02
Clinical Studies
No Clinical Studies information available for 5R01CA161001-02
News and More
Related News Releases
No news release information available for 5R01CA161001-02
History
No Historical information available for 5R01CA161001-02
Similar Projects
No Similar Projects information available for 5R01CA161001-02